Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Search by expertise, name or affiliation
Prot #2125-MEL-301: A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
Chandra, Sunandana
(PD/PI)
Medicine, Hematology Oncology Division
Project
:
Research project
Overview
Project Details
Status
Finished
Effective start/end date
4/9/19
→
9/23/20
Funding
Medpace Clinical Research LLC
(Prot #2125-MEL-301)
Idera Pharmaceuticals, Inc.
(Prot #2125-MEL-301)
View all
View less